Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Screen Targeting Lung and Prostate Cancer Oncogene Identifies Novel Inhibitors of RGS17 and Problematic Chemical Substructures.

Bodle CR, Schamp JH, O'Brien JB, Hayes MP, Wu M, Doorn JA, Roman DL.

SLAS Discov. 2018 Apr;23(4):363-374. doi: 10.1177/2472555217752301. Epub 2018 Jan 19.

2.

Evaluation of the Selectivity and Cysteine Dependence of Inhibitors across the Regulator of G Protein-Signaling Family.

Hayes MP, Bodle CR, Roman DL.

Mol Pharmacol. 2018 Jan;93(1):25-35. doi: 10.1124/mol.117.109843. Epub 2017 Oct 19.

3.

Natural Products Discovered in a High-Throughput Screen Identified as Inhibitors of RGS17 and as Cytostatic and Cytotoxic Agents for Lung and Prostate Cancer Cell Lines.

Bodle CR, Mackie DI, Hayes MP, Schamp JH, Miller MR, Henry MD, Doorn JA, Houtman JCD, James MA, Roman DL.

J Nat Prod. 2017 Jul 28;80(7):1992-2000. doi: 10.1021/acs.jnatprod.7b00112. Epub 2017 Jun 16.

4.

Development of a bimolecular luminescence complementation assay for RGS: G protein interactions in cells.

Bodle CR, Hayes MP, O'Brien JB, Roman DL.

Anal Biochem. 2017 Apr 1;522:10-17. doi: 10.1016/j.ab.2017.01.013. Epub 2017 Jan 20.

5.

RGS17: an emerging therapeutic target for lung and prostate cancers.

Bodle CR, Mackie DI, Roman DL.

Future Med Chem. 2013 Jun;5(9):995-1007. doi: 10.4155/fmc.13.91.

Supplemental Content

Loading ...
Support Center